US allows increased production of Takeda's ADHD drug to address shortage

The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's (4502.T) ADHD drug Vyvanse and its generic versions by about 24% to address the medicine's ongoing shortage in the United States.